- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: BRAF positive tumor
Total 42560 results
-
Novartis PharmaceuticalsRecruitingBRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid TumorJapan
-
National Cancer Center, JapanOno Pharmaceutical Co. LtdRecruitingPancreatic Cancer | Low-grade GliomaJapan
-
Novartis PharmaceuticalsRecruitingRare Unresectable or Metastatic BRAF V600E Mutation-positive Solid TumorsUnited States
-
Black Diamond Therapeutics, Inc.RecruitingMelanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditionsUnited States
-
Cancer Research UKRoyal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of BirminghamRecruitingGlioma | Melanoma | Carcinoma, Non-Small-Cell Lung | Multiple Myeloma | Colorectal Neoplasms | Ovarian Neoplasms | Solid Tumor | Thyroid Cancer, Papillary | Thyroid Carcinoma, Anaplastic | Laryngeal Neoplasms | Erdheim-Chester Disease | Haematological MalignancyUnited Kingdom
-
Carey Anders, M.D.Seagen Inc.RecruitingAdvanced Breast Cancer | Brain Metastases | Human Epidermal Growth Factor 2 Positive Carcinoma of BreastUnited States
-
Pierre Fabre MedicamentRecruitingMelanoma | Non-small Cell Lung Cancer | Solid Tumor, AdultUnited States, Australia, France, Spain, Taiwan, Korea, Republic of, China, Netherlands
-
Peter MacCallum Cancer Centre, AustraliaRecruitingMelanoma | MetastasisAustralia
-
Novartis PharmaceuticalsRecruiting
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingVemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaBRAF V600E Mutation Present | Papillary CraniopharyngiomaUnited States
-
PfizerCompleted
-
PfizerActive, not recruiting
-
Hoffmann-La RocheCompletedMetastatic MelanomaFrance, Italy, Spain, Brazil, Latvia, Germany, Hungary, Switzerland
-
Novartis PharmaceuticalsCompleted
-
Hoffmann-La RocheActive, not recruitingMelanomaUnited States, Korea, Republic of, United Kingdom, Australia, France, Belgium, Italy, Portugal, Spain, Brazil, Canada, Russian Federation, Germany, New Zealand, Israel, Poland, Greece, Austria, Hungary, Netherlands
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTerminatedPrimary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterCompletedPathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8United States
-
Novartis PharmaceuticalsCompletedBRAF-positive Metastatic MelanomaUnited States
-
Novartis PharmaceuticalsAvailable
-
ImmVira Pharma Co. LtdSuspendedMelanoma | Malignant MelanomaUnited States
-
Novartis PharmaceuticalsCompletedGlioblastoma | Astrocytoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma, Childhood and other conditionsUnited States, Italy, Japan, Germany, Spain, France, Canada, Australia, Brazil, Israel, Russian Federation, Argentina, United Kingdom, Finland, Belgium, Denmark, Czechia, Sweden, Switzerland, Netherlands
-
Sumitomo Pharma America, Inc.CompletedAdvanced Solid Tumors | Recurrent Ovarian Carcinoma | Colorectal Carcinoma | EGFR Positive Non-small Cell Lung Cancer | BRAF-Mutated MelanomaUnited States
-
Novartis PharmaceuticalsAvailable
-
Melanoma Institute AustraliaActive, not recruiting
-
Novartis PharmaceuticalsCompletedMelanomaUnited States, Belgium, Canada, Spain, United Kingdom, Netherlands, Argentina, Australia, Austria, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, New Zealand, Norway, Poland, Russian Federation, Sweden, Switz... and more
-
Novartis PharmaceuticalsCompletedBRAF Positive Metastatic MelanomaUnited States
-
Novartis PharmaceuticalsCompleted
-
Pierre Fabre MedicamentClinactCompletedMetastatic Colorectal Cancer | BRAF V600E Mutation PositiveFrance, United Kingdom, Spain, Belgium, Germany, Italy, Austria
-
Hoffmann-La RocheCompletedMalignant MelanomaUnited States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway
-
Novartis PharmaceuticalsCompletedMelanoma | CancerTaiwan, Thailand, China, Hong Kong, Korea, Republic of
-
Canadian Cancer Trials GroupNovartisTerminatedMelanoma | Brain MetastasesCanada
-
Novartis PharmaceuticalsCompletedMelanomaCanada, Spain, United Kingdom, Netherlands, United States, Argentina, Australia, France, Germany, Greece, Italy, Russian Federation, Sweden, Ukraine
-
Clinigen, Inc.Prometheus LaboratoriesTerminatedMetastatic MelanomaUnited States
-
Genentech, Inc.Completed
-
M.D. Anderson Cancer CenterCompletedSolid Tumor | Advanced CancerUnited States
-
Grupo Español Multidisciplinar de MelanomaRoche Farma, S.A; Pivotal S.L.Completed
-
Genentech, Inc.CompletedMetastatic Melanoma, BRAF V600 Mutation PositiveKorea, Republic of, Russian Federation, Israel, United States
-
University of California, San FranciscoTerminatedALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditionsUnited States
-
Hoffmann-La RocheCompletedMalignant MelanomaSouth Africa
-
Hoffmann-La RocheCompletedMalignant MelanomaUnited States, Australia
-
Hoffmann-La RocheCompleted
-
Novartis PharmaceuticalsCompletedMelanoma and Brain MetastasesCanada, United States, Australia, France, Germany, Italy, Spain
-
MedImmune LLCCompletedMelanomaItaly, United States, Canada, France
-
Novartis PharmaceuticalsCompletedCancerUnited States, Canada, Australia, France, Germany, Poland, Spain, United Kingdom, Italy
-
Hoffmann-La RocheCompletedMalignant MelanomaItaly, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden
-
GlaxoSmithKlineCompletedMelanomaUnited States, Italy, United Kingdom, France, Sweden, Germany, Poland, Australia, Belgium, Austria, Canada, Czechia, Greece, Russian Federation, Ukraine, Norway, Switzerland, New Zealand, Argentina
-
Hoffmann-La RocheCompletedMultiple Myeloma, NeoplasmsUnited States, China, France, Spain, United Kingdom, Germany
-
GlaxoSmithKlineCompletedCancerAustralia, United States, United Kingdom
-
GlaxoSmithKlineCompleted